Zortix
Sign in
BULLISHCore thesis · 5/5

Theravance sale to Beatrice likely at premium

The guest argued a sale of Theravance's assets to its partner Beatrice is the most likely outcome, based on a pattern of similar royalty-company acquisitions at significant premiums.

Sign in to read the full idea

The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.

NOT INVESTMENT ADVICE · A SUMMARY OF WHAT WAS SAID ON THE PODCAST · VERIFY AGAINST THE SOURCE
Theravance sale to Beatrice likely at premium · Zortix